Research programme: anticancer monoclonal antibody biosimilars - Dr Reddys Laboratories/Merck Serono
Latest Information Update: 16 Jul 2016
At a glance
- Originator Dr Reddys Laboratories; Merck Serono
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Switzerland (Parenteral)
- 08 Jun 2012 Preclinical trials in Cancer in Switzerland (Parenteral)